Massachusetts Kratom Users and Clinicians Warn Statewide Schedule I Ban Will Harm Low-Dose Medicinal Users

Why it matters

Massachusetts enacted one of the strictest kratom bans in the country — placing it in the same Schedule I category as heroin — but health providers and patients say the policy fails to distinguish between dangerous high-concentrate products and traditional botanical leaf, potentially criminalizing users who have no safer alternative for chronic pain and severe anxiety.

The big picture

The Massachusetts emergency ban went into effect August 28, 2026, the same day this article published, making it one of roughly 12 states with heavy restrictions. The policy debate mirrors a broader national tension: states acting ahead of federal regulation, using blunt tools that ban all kratom products rather than targeting the synthetic alkaloid extracts driving most overdoses. The DEA's own proposed 7-OH scheduling specifically exempts botanical kratom with naturally occurring concentrations, a distinction Massachusetts did not make.

Key findings

• A May 2026 study in the Journal of Addiction Medicine estimated more than 5 million Americans have used a kratom product in their lifetime — an all-time high.
• Detox centers in Massachusetts reported a surge from a handful of kratom-related admissions per year to roughly 12–15 per week, driven almost entirely by high-concentrate extract products.
• Clinicians warn that users dependent on high-dose products may switch to fentanyl or heroin to avoid withdrawal when products are unavailable.
• Low-dose native-leaf kratom users — who typically buy botanical powder online rather than from retail stores — face criminalization despite no documented link between their product type and serious adverse events.
• The DPH stated it is coordinating with treatment providers to prepare for withdrawal-related demand, but did not address the low-dose user population specifically.
• Four Massachusetts retailers filed suit on August 25 to block the ban, arguing the emergency order lacked required statutory findings for a Schedule I classification.

What they say

"There's a lot of controversy at the moment around kratom. I see a path forward in regards to creating a regulatory space where kratom leaf material, unaltered, can be available to the consumer," said Oliver Grundmann, clinical professor at the University of Florida College of Pharmacy and a leading kratom researcher.

Bottom line

Massachusetts' all-in Schedule I kratom ban took effect August 28, but health providers and patients are already warning it will push high-dose users toward fentanyl while criminalizing low-risk botanical leaf consumers who have no substitute.